Drug manufacturers Eli Lilly and Novo Nordisk’s denials of 340B drug discounts when covered entities use contract pharmacies are causing entities to lose more than a combined total of $125 million per month in 340B program savings, federal filings in lawsuits over the companies’ actions show.
Hospitals, health centers, and clinics are losing a total combined average of $62.3 million per month in 340B program savings due to Lilly’s denials of 340B pricing when drugs are shipped to contract pharmacies, the government said in a June 25 motion in Lilly’s lawsuit. Lilly’s policy applies to all covered entity types.
Drug manufacturers Eli Lilly and Novo Nordisk’s denials of 340B drug discounts when covered entities use contract pharmacies are causing entities to lose more than a combined total of $125 million per month in 340B program savings, federal filings in lawsuits over the companies’ actions show.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.